DeepMed Research

DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Evaluating Mass Spectrometry And Intraoperative MRI In The Advanced Multimodality Image Guided Operating Suite (Amigo) In Breast-Conserving Therapy

Not Applicable

Completed

Conditions: Breast Cancer Stage I
Early Stage Breast Cancer
Breast Cancer Stage II

Interventions: Procedure: Intra-operative Magnetic Resonance Imaging (MRI)
Other: Mass Spectrometer Analysis of Tissue Sample

First Posted Date: 2015-01-12

Last Posted Date: 2023-02-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 40

Registration Number: NCT02335671

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

Phase 2

Active, not recruiting

Conditions: HER-2 Positive Breast Cancer
Breast Cancer
Stage II Breast Cancer
Stage III Breast Cancer

Interventions: Drug: T-DM1
Drug: Pertuzumab
Procedure: Excision of tumor/mastectomy

First Posted Date: 2014-12-30

Last Posted Date: 2025-03-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 164

Registration Number: NCT02326974

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Tennessee Oncology/Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

and more 1 locations

Study of Individual Adult and Pediatric Patient Dose-escalated Interleukin-2 Therapy for Refractory Chronic GVHD

Phase 1

Completed

Conditions: Chronic Versus Graft Host Disease

Interventions: Drug: Interleukin-2

First Posted Date: 2014-12-17

Last Posted Date: 2020-06-23

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT02318082

Locations: 🇺🇸
Dana-Farber Cancer Insitute, Boston, Massachusetts, United States

Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM

Phase 1

Recruiting

Conditions: Glioblastoma

Interventions: Radiation: Radiation Therapy
Biological: Personalized NeoAntigen Peptides
Drug: Pembrolizumab
Biological: Poly-ICLC
Drug: Temozolomide

First Posted Date: 2014-11-10

Last Posted Date: 2024-12-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 56

Registration Number: NCT02287428

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Sexual Therapy and Rehabilitation After Treatment for Ovarian Cancer (START-OC): A Pilot Intervention

Not Applicable

Completed

Conditions: Ovarian Cancer

Interventions: Behavioral: Group Session
Behavioral: Telephone Coaching Session
Behavioral: Webinar

First Posted Date: 2014-11-10

Last Posted Date: 2020-02-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 53

Registration Number: NCT02287519

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Parental Decision-Making for Children With Relapsed Neuroblastoma

Active, not recruiting

Conditions: Relapsed Neuroblastoma

First Posted Date: 2014-11-04

Last Posted Date: 2024-07-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 96

Registration Number: NCT02282735

Locations: 🇺🇸
Stanford/Packard's Children's Hospital, Palo Alto, California, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Columbia University Medical Center, New York, New York, United States

and more 6 locations

Improving Informed Consent for Palliative Chemotherapy

Not Applicable

Completed

Conditions: Metastatic Colorectal Cancer
Unresectable Pancreatic Cancer
Metastatic Pancreatic Cancer

Interventions: Other: Usual, standard-of-care informed consent for chemotherapy
Other: Investigational informed consent for chemotherapy

First Posted Date: 2014-11-04

Last Posted Date: 2021-10-14

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 216

Registration Number: NCT02282722

Locations: 🇺🇸
Dana-Farber at Milford, Milford, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

and more 5 locations

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Phase 2

Completed

Conditions: Smoldering Myeloma
Smoldering Multiple Myeloma

Interventions: Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2014-10-31

Last Posted Date: 2023-06-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 51

Registration Number: NCT02279394

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

and more 6 locations

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care

Recruiting

Conditions: Melanoma
NSCLC

First Posted Date: 2014-10-30

Last Posted Date: 2025-02-05

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 840

Registration Number: NCT02279004

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

Recruiting

Conditions: Waldenstrom Macroglobulinemia
B-cell Malignancy, Low-grade
Myelodysplastic Syndrome With Low-grade Lesions
IgG Monoclonal Gammopathy of Uncertain Significance
Monoclonal Gammopathy of Undetermined Significance (MGUS)
Hematological Malignancies
Chronic Lymphocytic Leukemia (CLL)
Myelodysplastic Syndromes
Smoldering Multiple Myeloma

First Posted Date: 2014-10-21

Last Posted Date: 2025-04-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10000

Registration Number: NCT02269592

Locations: 🇺🇸
Dana Farber Cancer Institute at St. Elizabeth's, Brighton, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute at South Shore, Weymouth, Massachusetts, United States
🇺🇸
Dana Farber Cancer Institute at Merrimack Valley, Methuen, Massachusetts, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy